A Phase 3 interventional study of KVD900 600 mg and KVD900 300 mg in Hereditary Angioedema, sponsored by KalVista Pharmaceuticals, Ltd.. Completed at 71 sites in 23 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by KalVista Pharmaceuticals, Ltd. · Phase 3, Interventional, and Treatment
This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.
171 studies on the registry are indexed under Angioedemas, Hereditary; 25 are open to participants now.
This study's enrollment of 145 is above the median of 53 across 115 interventional studies indexed under Angioedemas, Hereditary.
Browse Angioedemas, Hereditary studies →KalVista Pharmaceuticals, Ltd. is the lead sponsor of 15 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients may roll over from KVD900-301.
Inclusion Criteria:
Exclusion Criteria:
Inadequate organ function, including but not limited to:
Drug: KVD900 600 mg
Drug: KVD900 300 mg
KVD900 Tablet 600 mg (2 x 300 mg)
KVD900 Tablet 300 mg
Frequencies and percentages of patients with AEs, AEs within 2 days of IMP administration, serious AE's and AEs causing premature discontinuation.
Time frame: AEs will be recorded from the first dose of IMP in the KVD900-302 trial up to and including the end of study (EOS) visit, a maximum of 2 years for each patient.
Number and percentage of patients with normal or abnormal laboratory results at each scheduled visit.
Time frame: Throughout the duration of the trial.
Number and percentage of patients with normal or abnormal vital sign results at each scheduled visit
Time frame: Throughout the duration of the trial.
Patient Global Impression of Change (PGI-C).
time to beginning of symptom relief defined as at least '' a little better'' (2 time points in a row)
Time frame: within 12 hours of initial dose of IMP administration.
Patient Global Impression of Severity (PGI-S): time to first incidence of 2 time points in a row decrease from baseline
Time frame: within 12 hours of initial dose of IMP administration.
PGI-S: time to HAE attack resolution
PGI-S: time to HAE attack resolution, defines as ''none''
Time frame: within 24 hours of initial dose of IMP administration.
Plan to share: No — Data will not be shared until all global regulatory filings are complete.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
KalVista Pharmaceuticals, Ltd.